Previous 10 | Next 10 |
Novocure (NVCR) has priced $500M of its 0% convertible senior unsecured notes due November 1, 2025 through a private placement.Initial purchasers granted an option to purchase additional $75M of notes.Closing date is November 5. Special interest on the notes, if any, will be payabl...
Initial conversion price represents a premium of approximately 50% Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% C...
Novocure (NVCR) to offer $500M of convertible senior notes due 2025, via a private placement. Initial purchasers have an option to purchase up to an additional $75M notes.Net proceeds will be used to further advance the company's clinical and product development programs and to invest in asso...
Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will ...
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2020 Earnings Call Transcript
Novocure Ltd (NVCR) Q3 2020 Earnings Conference Call October 29, 2020, 08:00 ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medical Officer Uri Wei...
The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q3 earnings call. For further details see: NovoCure Limited 2020 Q3 - Results - Earnings Call Presentation
Novocure (NVCR) has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are elec...
NovoCure (NVCR): Q3 GAAP EPS of $0.09 beats by $0.05.Revenue of $132.66M (+44.1% Y/Y) beats by $12.64M.Gross margin of 79% compared to 75% for Q3 2019.Active patients at period end 3.36M, +22% Y/Y; Prescriptions received 1.37M, +4% Y/Y.Press Release For further details see: NovoCur...
Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020 Quarterly net income of $9.3 million with $0.09 in earnings per share Novocure (NASDAQ: NVCR) today reported fi...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...